
Please try another search
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Name | Age | Since | Title |
---|---|---|---|
Martin A. Lehr | 40 | 2015 | Co-Founder, President, CEO & Director |
Andy Pasternak | 53 | 2025 | Independent Chairman |
Linda B. West | 66 | 2021 | Independent Director |
Jennifer Evans Stacey | 60 | 2021 | Independent Director |
Philip W. Kantoff | 70 | 2018 | Independent Director |
Luke N. Walker | 53 | 2024 | Independent Director |
Karen L. Smith | 57 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review